The Russian Direct Investment Fund and Panacea Biotec, announce cooperation to produce 100 million doses per year of Sputnik V, the world’s first registered vaccine against coronavirus.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund, commented:
“Vaccine partnerships are the only way to overcome the pandemic. The world continues its tight against coronavirus and we see a growing interest in Sputnik V vaccine as it is one of the best vaccines available. Cooperation with Panacea Biotec is an important step to produce the vaccine in India and to supply our international partners around the world.”
Dr. Rajesh Jain, Managing Director of Panacea Biotec, said:
“We are pleased to collaborate with RDIF to produce Sputnik V for global markets. Panacea Biotec brings decades of vaccine manufacturing and distribution know-how to scale-up Sputnik V supplies. Panacea Biotec will produce Sputnik V in its internationally accredited facilities· complying to strict GMP standards and prequalified by WHO.”